Yahoo! Finance: Biotechnology Industry News: Algeta initiates new oncology research program to evaluate the potential of a Targeted Thorium Conjugate (TTC) based on Immunomedics' anti-CD22 monoclonal antibody

Yahoo! Finance: Biotechnology Industry News The latest news on the Biotechnology industry from Yahoo! Finance

Algeta initiates new oncology research program to evaluate the potential of a Targeted Thorium Conjugate (TTC) based on Immunomedics' anti-CD22 monoclonal antibody Jan 28th 2013, 06:02 [Thomson Reuters ONE] - CD22 is a well-validated target for hematological cancers Oslo, Norway, 28 January 2013 - Algeta ASA (OSE: ALGETA) has initiated a new research program to evaluate a novel Targeted Thorium Conjugate ...

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions